- MK-677 (ibutamoren) is an orally active ghrelin-receptor agonist studied for raising growth hormone and IGF-1, investigated in clinical trials but not an approved drug.
- Some MK-677 trials in older adults included women, but menopause-specific dosing or response was not established, and figures circulating online are not female-specific.
- Estrogen is known to modulate the GH/IGF-1 axis, yet MK-677's interaction with estrogen status has not been characterized, so its behavior across female hormonal states is unstudied.
MK-677, also known as ibutamoren, is one of the more heavily discussed compounds in the growth-hormone conversation, partly because of one practical distinction: it works orally. It is a non-peptide agonist of the ghrelin receptor, and its oral bioavailability sets it apart from injectable secretagogues. That convenience has driven a lot of online interest, and a lot of dosing figures that are not actually female-specific.
The mechanism and where it has been studied
MK-677 is an agonist at the ghrelin, or growth-hormone-secretagogue, receptor (GHS-R1a). Through that receptor it is characterized for stimulating pulsatile growth-hormone release and raising IGF-1. It has been investigated in clinical trials in contexts such as growth-hormone deficiency, frailty, and catabolic states. It is not an approved drug, and those studies do not establish sex-specific regimens.
The reason MK-677 is notable for an endocrine catalog is the combination of an oral route with a defined secretagogue mechanism. That combination is what has been characterized; it is not, on its own, a demonstrated outcome in any specific population.
What the trials did and did not settle for women
This is where MK-677 differs from the earlier compounds in this catalog. Some of its clinical trials, particularly in older adults, did include women. That is more than many research peptides can say. But inclusion is not the same as sex-stratified reporting, and it is not the same as an established female dose or response.
| Question a woman might ask | Current evidence state |
|---|---|
| Were women included in trials? | Yes, some trials in older adults enrolled women. |
| Is there a female-specific dose or response? | No, sex-stratified dosing and response are not established. |
| Does it interact with estrogen status? | Not characterized, though estrogen is known to modulate the GH/IGF-1 axis. |
| Menopause-specific data? | No dedicated menopause dosing or response established. |
| Menstrual cycle interactions? | No studies examine this. |
The estrogen point deserves emphasis. The growth-hormone and IGF-1 axis is genuinely estrogen-sensitive; oral estrogen, for instance, is well documented to shift IGF-1 dynamics. So a compound acting on that axis raises an obvious female-physiology question. The honest answer is that MK-677's interaction with estrogen status has not been characterized, which makes it an open question rather than a resolved one.
Once-daily oral dosing has appeared in clinical studies, and those figures are reported here strictly for reference. This site does not publish personal dosing, titration, or protocols, and the online figures that circulate are not female-specific. Nothing here is medical advice.
The remaining gaps
- Menstrual cycle: no studies examine menstrual cycle interactions.
- Hormonal interactions: estrogen modulates the GH/IGF-1 axis, but MK-677's interaction with estrogen status is not characterized.
- Pregnancy and lactation: no safety data exists, and absence of harm data is not evidence of safety.
- Perimenopause and menopause: some trials in older adults included women, but menopause-specific dosing or response was not established.
- Sex differences: clinical studies have included female participants, but sex-stratified dosing and response are not established.
MK-677 is a case where female evidence is best described as partial: real trial inclusion, no sex-specific conclusions. The MK-677 compound profile shows how that translates into the evidence grade and the standalone female-evidence fields. Where women were enrolled, we say so; where their outcomes were never separated out, we say that too.